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Bisphenol A Regulates sodium 
Ramp Currents in Mouse Dorsal 
Root Ganglion Neurons and 
Increases Nociception
sergi soriano1,2, Minerva Gil-Rivera  1, Laura Marroqui2, Paloma Alonso-Magdalena2, 
esther Fuentes2, Jan-Ake Gustafsson3,4, Angel Nadal  2 & Juan Martinez-pinna1,2
17β-Estradiol mediates the sensitivity to pain and is involved in sex differences in nociception. The 
widespread environmental disrupting chemical bisphenol A (BPA) has estrogenic activity, but its 
implications in pain are mostly unknown. Here we show that treatment of male mice with BPA (50 µg/
kg/day) during 8 days, decreases the latency to pain behavior in response to heat, suggesting increased 
pain sensitivity. We demonstrate that incubation of dissociated dorsal root ganglia (DRG) nociceptors 
with 1 nM BPA increases the frequency of action potential firing. SCN9A encodes the voltage-gated 
sodium channel Nav1.7, which is present in DRG nociceptors and is essential in pain signaling. Nav1.7 
and other voltage-gated sodium channels in mouse DRG are considered threshold channels because 
they produce ramp currents, amplifying small depolarizations and enhancing electrical activity. 
BpA increased Nav-mediated ramp currents elicited with slow depolarizations. Experiments using 
pharmacological tools as well as DRG from eRβ−/− mice indicate that this BPA effect involves ERα and 
phosphoinositide 3-kinase. The mRNA expression and biophysical properties other than ramp currents 
of Nav channels, were unchanged by BPA. Our data suggest that BPA at environmentally relevant doses 
affects the ability to detect noxious stimuli and therefore should be considered when studying the 
etiology of pain conditions.
Bisphenol A (BPA) is an endocrine-disrupting chemical that acts as a xenoestrogen, among other mechanisms 
of action1. BPA is produced in large quantities in the manufacture of polycarbonate plastics and epoxy resins and 
it is released from common household materials, including polycarbonate plastics, the lining of food cans and 
thermal paper, which may explain why 93% of the U.S. population presented measurable amounts of BPA in their 
urine2. BPA exposure has been associated with several hormone-related diseases, including obesity and diabe-
tes, female and male reproductive alterations, hormone-sensitive cancers, thyroid hormone level disruption and 
important alterations of the nervous system3.
One important effect of BPA on the nervous system, which remains poorly understood, is the alteration of 
pain sensation. Behavioral in vivo studies reported that male and female rats perinatally treated with 40 μg/kg/
day BPA (an environmentally relevant dose orally administered) presented increased pain sensitivity or hyper-
algesia4, indicating that nociceptive neurons may be altered. As reported in this previous study, BPA increased 
the frequency with which animals lick an area of the body injured by a formalin injection. This is probably a 
supraspinal-mediated response involving opioid circuits of the limbic system; however, a direct action of BPA 
on nociceptors could also be involved. In female rats, the ability of BPA to increase estradiol plasma levels in 
female rats could have contributed to the effects. In a multibehavioral in vivo model of migraine, treatment of 
adult ovariectomized rats with 500 μg/kg/day BPA (intraperitoneally administered) exacerbates migraine-like 
behavior, including locomotor activity, light and sound aversion and grooming (indicating facial allodynia). 
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Importantly, alongside these symptoms of nociceptive hypersensitivity, trigeminal neurons showed an increased 
mRNA expression of estrogen receptors, extracellular signal–regulated kinases (ERK1/2) and Nav1.8 encoding 
Na+ channels5. However, 500 μg/kg/day of BPA intraperitoneally administered may not be considered an environ-
mentally relevant dose6. As a conclusion, although BPA seems to be involved in altered nociception, no study has 
yet investigated the BPA effects on nociceptors in vitro at doses that are relevant to human exposure.
Numerous studies on both animals and humans have demonstrated that the natural hormone 17-β estradiol 
(E2) regulates pain sensitivity and plays a role in gender differences7. A series of studies have unveiled at least five 
molecular mechanisms involved in this E2 effect. Firstly, an increased glutamate N-methyl-D-aspartate (NMDA) 
receptor expression and phosphorylation in spinal neurons processing visceral nociception8. Secondly, regulation 
of P2X2-mediated peripheral pain by acting on estrogen receptors α (ERα) and GPR30 receptors expressed in 
primary afferent neurons through the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)-ERK1/2 
intracellular pathway9. Thirdly, potentiation of acid-sensing ion channels in DRG neurons via an ERα and 
ERK1/2 signaling pathway10 Fourthly, upregulation of transient receptor potential vanilloid 1 (TRPV1) channels 
via E2-induced genomic and nongenomic mechanisms11 and fifthly, upregulated the expression of voltage-gated 
sodium channels Nav1.7, probably through ERα12. Therefore, given that E2 affects pain behavior, it is interesting 
to further characterize the actions of BPA, acting as a xenostrogen, on pain. Indeed previous results of our group 
have shown that BPA acts as a potent estrogen within the 1–100 nM range in excitable cells, e.g., pancreatic 
β-cells, via extranuclear estrogen receptors ERα and ERβ13,14. In pancreatic β-cells, BPA acts through extranu-
clear ERα and ERβ to modify the shape of action potentials as well as electrical activity which result from altered 
expression and biophysical properties of voltage-gated calcium-channels15. Other changes to ion channel activity 
have been observed in response to BPA, although normally using high doses within the 10–100 µM range16–19.
In the present study, we show that adult male mice treated with 50 μg/kg/day BPA for 8 days presented 
increased pain sensitivity to heat. To understand how BPA exacerbated pain sensation, we isolated DRG neurons 
and studied their electrical activity. We found that 1 nM BPA increased the frequency of action potential firing of 
DRG neurons in response to current injection by increasing the magnitude of Nav ramp currents. Furthermore, 
the natural hormone E2 (1 nM) increased the magnitude of ramp current to a similar extent. Nav1.7 sodium chan-
nels play a pivotal role in initiating action potentials in response to depolarization of sensory neurons by noxious 
stimuli20, and loss-of-function mutations of the underlying gene, SCN9A, provoke an inability to feel pain21. In 
contrast, gain-of-function mutations of SCN9A cause severe pain disorders such as inherited erythromelalgia and 
paroxysmal extreme pain disorder22. The effect of BPA on Nav ramp currents reported here was mediated by the 
activation of the estrogen receptor ERα in a pathway involving phosphoinositide 3-kinase (PI3K).
Results
BPA treatment increases thermal nociception. To analyze if BPA had an action on pain sensitivity in 
vivo, we used adult mice treated with subcutaneous injection of either 50 µg/kg/day BPA or vehicle for 8 days. 
We observed that the latency to the onset of the pain response following exposure to a metallic hot plate at 50 °C 
decreased in BPA-treated animals (Fig. 1). One day post-treatment, the delay was 14.3 ± 1.1 s, n = 10 for BPA expo-
sure, compared to 20.7 ± 2 s, n = 10 for controls (p < 0.05; Fig. 1). This BPA-induced reduction was maintained for 
4 days after the end of the treatment (Fig. 1). It should be noted that the vehicle on its own caused a small reduction 
in the latency of the pain response, as previously reported, thus BPA exerted an action in addition to this effect23.
BPA increases excitability in dorsal root ganglion neurons. To study whether BPA directly affects 
sensory neurons, we performed current-clamp studies in small-diameter DRG neurons (<30 μm) incubated with 
1 nM BPA or vehicle for 24–48 h. BPA had no significant effect on input membrane resistance, input membrane 
capacitance or action potential amplitude (control, 987 ± 111 MΩ, n = 26 vs BPA, 838 ± 81 MΩ, n = 21; control, 
12.0 ± 0.6 pF, n = 26 vs BPA, 11.1 ± 1.1 pF, n = 21; control, 107.3 ± 3.1 mV, n = 26 vs BPA, 97.8 ± 3.8 mV, n = 21, 
respectively). In contrast, the resting membrane potential of neurons exposed to BPA was depolarized by 5 mV 
(control, −56.5 ± 1.5 mV, n = 26 vs BPA, −51.5 ± 1.8 mV, n = 21; *p < 0.05). We therefore measured the threshold 
current required to elicit an action potential using a series of 1 s duration current injections, increasing in final 
Figure 1. BPA treatment enhances the thermal nociception. Bar graphs showing the average latency of pain 
reflexes using the hot plate at a fixed temperature of 50 °C in control animals (black bars, n = 10) and animals 
treated with subdermal injection of BPA (50 µg/kg/day, blue bars, n = 10) for 8 days. Control animals were 
injected with the same volume of vehicle as the BPA group each day (100 μL of corn oil). Data are represented 
as the mean ± s.e.m (N = 20 animals). One-way ANOVA for repeated measures: *p < 0.05; **p < 0.01; ns, not 
significant. (1 day post: p = 0.046; 4 day post: p = 0.007; 7 day post: p = 0.073; 10 day post: p = 0.27).
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amplitude by 10 pA between each successive stimulus. Representative responses of control and BPA-treated neu-
rons to different current inputs are illustrated in Fig. 2A–F. There was a marked reduction of approximately 38% of 
the current threshold for single action potential generation in BPA-treated neurons (control, 52.7 ± 6.3 pA, n = 26 
vs BPA, 20.0 ± 3.7 pA, n = 21; ***p < 0.0001; Fig. 2G). In addition, although the frequency of action potential 
firing at the threshold current was similar in both groups (control, 1.16 ± 0.07 Hz, n = 26 vs BPA, 1.55 ± 0.27 Hz, 
n = 21; Fig. 2H), an injection of +80 pA elicited three times the number of action potentials in BPA compared to 
vehicle treated neurons (10.8 ± 1.8 Hz, n = 21 for BPA vs 3.2 ± 0.8 Hz, n = 26 for control; ***p < 0.001; Fig. 2I). 
Similar differences in the frequency of action potential firing were observed for a larger current injection (control, 
4.1 ± 1.1 Hz, n = 26 vs BPA, 11.0 ± 1.8 Hz, n = 21; **p < 0.001; Fig. 2J).
Nav1.7, Nav1.8 and Nav1.9 mRNA expression are unaffected by BPA. The Nav1.7 channel is 
expressed in the peripheral nervous system, is sensitive to tetrodotoxin (TTX)24,25 and plays a key role in initi-
ating action potentials in nociceptive neurons26. In addition to Nav1.7, also Nav1.8 and Nav1.9 are expressed in 
peripheral neurons and have been linked to pain pathways27.
To examine whether Nav1.7, Nav1.8 and Nav1.9 expression in DRG neurons were affected by BPA, we meas-
ured their mRNA levels by quantitative RT-PCR in DRG neurons treated with 1 nM BPA or vehicle for 24–48 h. 
The results indicate that 24–48 h of 1 nM BPA treatment did not affect voltage-dependent sodium channel gene 
transcription (Fig. 3A–C).
Figure 2. BPA treatment increases excitability in DRG neurons. Representative voltage traces from small 
dorsal root ganglion neurons in current-clamp experiments in control conditions (A–C; black traces) and in 
the presence of 1 nM BPA for 24–48 h (D–F; blue traces) in response to different levels of current injection 
(threshold, +80 and +100 pA). (G) Bar graph showing the average current threshold (pA) for action potential 
firing in control (n = 26 cells, black bar) and in 1 nM BPA-treated neurons (n = 21 cells, blue bar). (H) Bar graph 
showing the average frequency of action potential firing (Hz) at current threshold injection in control (n = 26 
cells, black bar) and in 1 nM BPA-treated neurons (n = 21 cells, blue bar). (I) Bar graph showing the average 
frequency of action potential firing (Hz) at +80 pA current injection in control (n = 26 cells, black bar) and 
in 1 nM BPA-treated neurons (n = 21 cells, blue bar). (J) Bar graph showing the average frequency of action 
potential firing (Hz) at +100 pA current injection in control (n = 26 cells, black bar) and in 1 nM BPA-treated 
neurons (n = 21 cells, blue bar) Data are represented as the mean ± s.e.m (N = 8 animals). Student’s t-test: 
**p < 0.01; ***p < 0.001; ns, not significant. (G: p = 0.0001, t = 4.197, df = 45; H: p = 0.22, Mann-Whitney 
U = 211.0; I: p < 0.0001, Mann-Whitney U = 72.50; J: p = 0.001, t = 3.495, df = 41).
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Figure 3. BPA treatment does not affect the expression of sodium channels or the amplitude of TTX-sensitive 
or Nav1.8 currents in DRG neurons. (A–C) Bar graphs showing the relative expression of Scn9a (Nav1.7), Scn10a 
(Nav1.8) and Scn11a (Nav1.9), respectively (in control neurons (black bars) and BPA-treated neurons (blue 
bars). The mRNA expression of the sodium channels was analyzed by quantitative RT-PCR and was normalized 
by housekeeping gene Hprt. The results were obtained from three different preparations of dissociated DRG 
neurons from 6 male mice (experiments performed in duplicate). (D–F) Representative voltage-clamp 
current recordings showing TTX-sensitive plus Nav1.8 currents, Nav1.8 currents and TTX-sensitive currents, 
respectively. To obtain isolated TTX-sensitive currents, Nav1.8 currents were subtracted from TTX-sensitive 
plus Nav1.8 currents. See Methods section for a detailed explanation. Insets in the top of panels D and E show 
the voltage protocol used. Only the currents obtained with test pulses (−80 to +50 mV, 5 ms) are shown. 
Calibration bars in (D) apply to (E,F). (G,H) Representative relationship between sodium currents density (J, 
sodium currents normalized to cell size in pF) and the voltage of the test pulse in control (black circles) and 
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In addition, we measured the mRNA levels of TRPA1 and TRPV1 in DRG neurons treated with 1 nM BPA, 
because these TRP channels mediate pain28. The expression of these TRP channels also remained unchanged by 
BPA treatment (Supplemental Fig. 1).
Amplitude of sodium currents is unaffected by BPA. To study whether BPA functionally affect 
Nav currents independently of transcriptional effects, we recorded voltage-gated sodium currents using the 
patch-clamp technique in the whole-cell configuration of small-diameter DRG neurons (<30 μm). Cell size 
was measured using average capacitance29 which was 14.6 ± 1.5 pF for vehicle (n = 18) and 13.8 ± 1.1 pF for 
BPA-treated group (n = 16). Based on their size, this group of neurons is preferentially nociceptive26,30,31. As men-
tioned above, sodium channels Nav1.7, Nav1.8 and Nav1.9 were expressed in peripheral neurons. To measure the 
amplitude of TTX-sensitive sodium currents, including a large amount of Nav1.7 current, but probably with some 
Nav1.6 current, we combined two electrophysiological protocols32. Briefly, an I–V curve family of TTX-sensitive 
and Nav1.8 (TTX-resistant) currents was recorded using a holding potential of −80 mV, which inactivates Nav1.9 
channels33. Because some of the TTX-sensitive current is also inactivated at −80 mV, a long prepulse of 500 ms 
at a potential of −120 mV was applied to remove the fast inactivation of TTX-sensitive currents, yet maintain-
ing Nav1.9 inactivation33. This produced an estimation of the total Na+ current produced by TTX-sensitive and 
Nav1.8 (Fig. 3D). To reveal the TTX-sensitive current in isolation, a family of currents was recorded using a pre-
pulse of 500 ms to −50 mV, which inactivated the TTX-sensitive current while leaving the Nav1.8 current intact 
(Fig. 3E). Then, we subtracted Nav1.8 currents (Fig. 3E) from TTX-sensitive + Nav1.8 currents (Fig. 3D) to only 
visualize TTX-sensitive currents (Fig. 3F). When normalized sodium currents (pA/pF; JNa+) were represented 
vs voltage pulse, we observed no significant differences between BPA-treated and vehicle-treated DRG neurons, 
either for TTX-sensitive or Nav1.8 currents (Fig. 3G,H, respectively, representative J-V curves). The threshold 
activation voltage and the voltage of the peak current were not affected by BPA (Fig. 3G,H), nor was the average 
peak current densities of either the TTX-sensitive currents or Nav1.8 channels (Fig. 3I,J, respectively).
BpA increased the amplitude of Nav ramp currents. The biophysical properties of Nav1.7 make it 
well-suited for low frequency firing of nociceptive C-fibers because it produces rapidly activating and inactivat-
ing currents, yet displays a slow recovery from inactivation. It is of note that Nav1.7 is characterized by a slow 
closed-state inactivation, allowing the channel to produce a ramp current in response to small, slow depolariza-
tions, such as the receptor potentials generated by the by the pain mediators prostaglandins, histamine, ATP and 
serotonin. The ramp current evoked with the receptor potential depolarizes the cell and increases the probability 
that the neuron will reach the threshold and fire action potentials26,34. Hence, we investigated whether 1 nM 
BPA directly affected the biophysical properties of Nav currents. Neither the fast inactivation nor the recovery 
from inactivation were affected by BPA (see Fig. 4A,B). However, 1 nM BPA increased the Nav ramp current in 
response to a ramp of 600 ms duration from −100 to +20 mV (Fig. 4C). The average ramp current measured at 
the peak increased from the control level of 1.76 ± 0.25% of Itrans, n = 18 to 4.46 ± 1.03% of Itrans, n = 16 for BPA; 
*p < 0.05; Fig. 4D). This effect was similar when the natural hormone 17β-estradiol was used at 1 nM instead of 
BPA (Fig. 4E).
BpA-increased Nav ramp currents involve estrogen receptor ERα. DRGs express estrogen recep-
tors ERα and ERβ35. We sought to investigate whether they had a role in the action of BPA on Nav ramp currents. 
When DRG neurons were incubated with a specific agonist of ERα, propyl pyrazole triol (PPT, 1 nM), the ramp 
current was statistically increased (control, 2.18 ± 0.6% of Itrans, n = 5 vs PPT, 5.2 ± 1.07% of Itrans, n = 5; *p < 0.05; 
Fig. 5A). Furthermore, BPA had no effect of the ramp current in the presence of a specific antagonist of ERα, 
methyl-piperidino-pyrazole (MPP, 100 nM), (MPP, 2.62 ± 0.64% of Itrans, n = 8 vs MPP + BPA, 3.24 ± 0.85% of 
Itrans, n = 8; Fig. 5B). The incubation of DRG neurons with MPP alone had no effect on ramp currents (compare 
control in Fig. 5A with MPP alone in Fig. 5B). These experiments strongly suggest that ERα rather than ERβ is 
responsible for the effect of BPA on Nav ramp currents. The lack of contribution of ERβ was further supported 
by the lack of effect of a specific agonist of ERβ, diarylpropionitrile (DPN, 1 nM) on the ramp currents(control, 
2.64 ± 1.2% of Itrans, n = 5 vs DPN, 2.44 ± 0.97% of Itrans, n = 5; Fig. 5C). Furthermore, 1 nM BPA in the presence 
of a specific antagonist of ERβ, phenyltrifluoromethyl pyrazolopyrimidine (PHTPP, 10 μM), increased ramp cur-
rents (PHTPP, 0.44 ± 0.13% of Itrans, n = 6 vs PHTPP + BPA, 2.45 ± 0.71% of Itrans, n = 13, *p < 0.05; Fig. 5D). 
As the Nav ramp current values in the presence of the PHTPP were considerably reduced in comparison to the 
ramp current values in the rest of the experiments, we wanted to further confirm the lack of participation of ERβ, 
and the contribution of ERα, in the effect of BPA on Nav ramp currents. To do this, we used DRG neurons from 
ERβ−/− mice. Incubation of DRG neurons from ERβ−/− male mice with 1 nM BPA increased the ramp current to 
a similar extent as in wild-type animals (control, 2.02 ± 0.71% of Itrans, n = 9 vs BPA, 7.43 ± 1.79% of Itrans, n = 9, 
*p < 0.01; Fig. 5E). Moreover, the ramp currents of DRG neurons from ERβ−/− male mice incubated with the 
vehicle (control in Fig. 5E) had similar ramp currents to vehicle-treated DRG neurons from wild-type animals 
(controls in Figs 4D, 5A,C).
1 nM BPA-treated cells (blue circles) for TTX-sensitive and Nav1.8 currents, respectively. (I,J) Average peak 
current density in control cells (black bar; n = 18 cells) and 1 nM BPA-treated cells (blue bar; n = 16 cells) 
obtained from J-V relationships for TTX-sensitive and Nav1.8 currents, respectively. Data are represented as the 
mean ± s.e.m (N = 11 animals). Student’s t-test: ns, not significant. (A; p = 0.17, t = 1.448, df = 12. B; p = 0.13, 
t = 1.607 df = 12; C; p = 0.81, t = 0.244 df = 12).
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potentiation of Nav ramp currents by BPA involves phosphoinositide 3-kinase. ERα acts outside 
the nucleus through activation of PI3K and extracellular signal–regulated kinases (ERK1/2) signaling pathways, 
among others36–38. In pancreatic β-cells, ERα-mediated actions involved these two kinases15,39. To investigate 
whether PI3K plays a role in the potentiation of Nav ramp currents by BPA, we measured the ramp currents in 
DRG neurons incubated with 1 nM BPA in the presence or absence of the broad-spectrum PI3K inhibitor wort-
mannin (100 nM). We observed that the BPA-induced potentiation of the ramp currents was strongly reduced 
by wortmannin (control, 1.50 ± 0.49% of Itrans, n = 11 vs BPA, 4.16 ± 0.71% of Itrans, n = 10; **p < 0.01 and BPA vs 
wortmannin + BPA, 2.17 ± 0.36% of Itrans, n = 14; **p < 0.01; Fig. 5F), while wortmannin itself had no effect on 
the ramp currents (1.49 ± 0.34% of Itrans, n = 12, Fig. 5F). Furthermore, the effects of BPA on resting membrane 
potential and firing frequency (see above) were abolished in the presence of wortmannin (Supplemental Fig. 2). 
This result indicates that the potentiation of Nav ramp currents by BPA involves PI3K. ERK1/2 has also been 
observed to induce phosphorylation of Nav and modulation of its gating properties, thereby contributing to the 
regulation of DRG neuron excitability40. We therefore assessed the involvement of this cellular pathway in the 
action of BPA on Nav ramp currents. However, incubation of DRG neurons with the specific ERK1/2 inhibitor 
2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059, 10 μM) had no effect on the BPA-induced 
Figure 4. BPA increases the amplitude of Nav ramp currents in DRG neurons. (A) Average relationship between 
normalized sodium currents (I/Imax) evoked with the test pulse (−10 mV, 5 ms) and the voltage of the prepulse 
(−140 to −10 mV, 500 ms) for the measurement of the steady-state fast inactivation in control (black circles, n = 18 
cells) and 1 nM BPA-treated neurons (blue circles, n = 16 cells). Inset shows the entire voltage protocol (bottom) 
and the current recorded with the test pulse (−10 mV, 5 ms). (B) Average relationship between the recovery from 
inactivation of sodium currents induced by two identical voltage steps (−80 to −10 mV, 10 ms; measured as a 
percentage) and the time between these two pulses (∆t, in ms) in control (black circles, n = 18 cells) and 1 nM BPA-
treated neurons (blue circles, n = 16 cells). Inset shows the voltage protocol (bottom) and the currents recorded 
with the two pulses when ∆t = 20 ms. (C) Representative recording showing the Nav ramp current in response 
to a voltage ramp of 600 ms duration from −100 to +20 mV in a control (black trace) and a 1 nM BPA-treated 
neuron (blue trace). (D) Bar graph showing the average Nav ramp currents in control (n = 18 cells, black bar) 
and 1 nM BPA-treated neurons (n = 16 cells, blue bar) for 24–48 h. (E) Bar graph showing the average Nav ramp 
currents in control (n = 5 cells, black bar) and 1 nM 17-β estradiol (E2) (n = 5 cells, green bar) for 24–48 h. Ramp 
currents in (C–E) are expressed as a percentage of the peak of the transient Nav current. Data are represented as the 
mean ± s.e.m (N = 5 animals, same animals employed in Fig. 3). (A,B) Student’s t-test: not significant for all points 
tested. Student’s t-test: *p < 0.05. (D; p = 0.01, t = 2.610, df = 32. E; p = 0.04, t = 2.57, df = 6).
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potentiation of the ramp currents (control, 2.02 ± 0.42% of Itrans, n = 9 vs PD98059 + BPA, 4.68 ± 0.96% of Itrans, 
n = 10; *p < 0.05; PD98059, 1.21 ± 0.33% of Itrans, n = 5 vs PD98059 + BPA, 4.68 ± 0.96% of Itrans, n = 10; *p < 0.05, 
Fig. 5F). It should be noted that PD98059 itself had no effect on the ramp currents (PD98059, 1.21 ± 0.33% of 
Itrans, n = 5 vs control, 2.02 ± 0.42% of Itrans, n = 9; ns, Fig. 5F).
Figure 5. BPA enhances ramp currents through ERα/PI3K signaling pathway. (A) Bar graph showing the 
average Nav ramp currents in control DRG neurons (n = 5 cells, black bar) and in the presence of the specific 
ERα agonist propyl pyrazole triol (PPT, 1 nM) (n = 5 cells, light gray bar). (B) Bar graph showing the average 
Nav ramp currents in the presence of the specific ERα antagonist methyl-piperidino-pyrazole (MPP, 100 nM) 
(n = 8 cells, black bar) and in the presence of MPP and 1 nM BPA (n = 8 cells, blue bar) in DRG neurons. 
(C) Bar graph showing the average Nav ramp currents in control (n = 5 cells, black bar) and in the presence 
of the specific ERβ agonist diarylpropionitrile (DPN, 1 nM) (n = 5 cells, dark-gray bar) in DRG neurons. 
(D) Bar graph showing the average Nav ramp currents in the presence of the specific ERβ antagonist phenyl 
trifluoromethyl pyrazolo pyrimidin (PHTPP, 10 μM) (n = 6 cells, black bar) and in the presence of PHTPP and 
1 nM BPA (n = 13 cells, blue bar) in DRG neurons. (E) Bar graph showing the average Nav ramp currents in 
control (n = 9 cells, black bar) and in the presence of 1 nM BPA (n = 9 cells, blue bar) in DRG neurons from 
ERβ−/− mice. (F) Bar graph showing the average Nav ramp currents in control DRG neurons (n = 11 cells, black 
bar), in the presence of 1 nM BPA (n = 10 cells, blue bar), in the presence of 1 nM BPA and 100 nM wortmannin 
(n = 14 cells, gray bar), in the presence of 100 nM wortmannin alone (n = 12 cells, white bar), in the presence of 
1 nM BPA and 10 µM PD98059 (n = 10 cells, blue bar) and in the presence of 10 µM PD98059 alone (n = 5 cells, 
pink bar) in DRG neurons. Ramp currents in all panels are expressed as a percentage of the peak of the transient 
Nav current. Data are represented as the mean ± s.e.m (N = 11 animals). Panels (A-E): Student’s t-test: *p < 0.05; 
**p < 0.01; ns, not significant. (A; p = 0.02, t = 2.747, df = 8. B; p = 0.54, t = 0.62 df = 14; C; p = 0.88, t = 0.14 
df = 8; D; p = 0.03, t = 2.27 df = 16; E; p = 0.005, t = 3.281 df = 15). Panel (F): one-way ANOVA followed by 
Holm-Sidak; **p < 0.01, *p < 0.05. (control vs 1 nM BPA: p = 0.003, t = 3.72; 1 nM BPA vs 1 nM BPA + 100 nM 
WORT: p = 0.02, t = 2.95; 1 nM BPA + 10 µM PD98059 vs 10 µM PD98059; p = 0.02, t = 2.92; control vs 10 µM 
PD98059: p = 0.50, t = 0.67; control vs 1 nM BPA + 10 µM PD98059; p = 0.02, t = 2.66).
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Discussion
Exposure to bisphenol A, an endocrine-disrupting chemical, has been linked to several diseases, including disrup-
tion of the nervous system3. Evidence points to a role of BPA at environmentally relevant doses of 40 μg/kg/day in 
increasing the perception of noxious stimuli4 and under high exposures such as 5 mg/kg/day41 and 500 μg/kg/day5. 
The findings described here indicate that subcutaneous injection of BPA, at the tolerable daily intake recom-
mended by the US EPA (50 µg/kg/day), increased the sensitivity to thermal pain in mice treated for eight days 
using the hot-plate test at a temperature of 50 °C. This exacerbated pain behavior may involve a direct action of 
BPA on sensory neurons or an effect on the central nervous system, or both. Our results using DRG neurons 
exposed in vitro to 1 nM BPA indicate that primary sensory neurons are indeed directly affected by BPA exposure, 
although we cannot rule out an effect on supraspinal neuronal circuits involved in pain processing, as reported 
elsewhere4. The fact that in the vehicle-treated group (control) a decrease in the latency to pain response was 
observed, suggests a habituation to the test, as observed previously23. Furthermore, in the days post-treatment 
that can be observed in Fig. 1 (days 1, 4, 7 and 10 post) no vehicle or BPA was injected to the animals, allowing 
for a full washout of the compound and confirming the interpretation that the augmented response to pain was 
dependent on BPA presence. It should be noted that the hot-plate test in the present study did not assess the pain 
threshold nor use other thermal pain tests, such as the tail-flick response or other assessments of nociceptive 
mechanical stimuli. Therefore, the fact that the in vivo effect of BPA was only assessed with the hot-plate test at a 
fixed temperature must be considered as a limitation of our study. More extensive future studies of such actions of 
BPA would be worthwhile to assess pain responses other than thermal pain.
A central observation in the present study is that a concentration of BPA typically found in human blood 
(1 nM)42,43 altered the slow closed-state inactivation voltage-gated Nav channels in cultured primary neurons. The 
consequence of this effect is to enhance ramp currents in response to small depolarizations and thereby action 
potential generation, a fundamental role of voltage-gated sodium channels in excitable cells. Genetic, structural 
and functional studies have shown that the Nav1.7 subunit is a major contributor to pain perception26. The fact 
that 1 nM BPA increases the Nav ramp currents in DRG neurons, including Nav1.7, implies that the amplification 
of weak stimuli to reach the threshold for firing action potentials is increased in the neurons bearing Nav chan-
nels. As a consequence, the excitability of these neurons is augmented, and then the transmission of the pain sig-
nal will be facilitated. This would mechanistically explain our results in in vivo experiments in which the thermal 
pain behavior was increased by BPA injection.
Regarding the rationale of BPA dosing levels, we have selected 50 μg/kg/day for in vivo experiment and 1 nM for 
in vitro experiments, as these doses are within the range of human exposure and employed in many studies13,42,44,45. 
We have recently published that BPA affects the electrical activity of the excitable pancreatic β–cell in a 
non-monotonic dose-response relationship, with 1 nM BPA being the most effective concentration15. In addition, 
in a previous paper of our group, we reported an effect of 1 nM BPA on ion channel gating in pancreatic β–cells 
from human islets14. For these reasons, we feel that the selected doses in the present study are appropriate for a 
first description of the molecular mechanisms of BPA action in pain signaling.
Although the current work is based upon murine studies, it should be noted that the pharmacokinetics of BPA 
is similar between mice and humans, with comparable serum-conjugated BPA levels over the 24 h period after 
BPA administration46. It could be argued that oral administration is a more relevant route of exposure to compare 
with human exposure, however previous work has shown that subcutaneous exposure represents a better means 
of ensuring a ratio of serum conjugated vs unconjugated BPA within the range observed in human studies6. 
Nevertheless, the correlation between BPA dose administered and average serum concentration achieved is not 
exempt from controversy and remains under study in our laboratory.
As outlined above, small DRG neurons express Nav1.8 and Nav1.9 in addition to Nav1.7. Although Nav1.8 
produces most of the current underlying the depolarizing phase of action potential47, a contribution of Nav1.8 
to ramp currents has also been reported48. However, this contribution of Nav1.8 occurs preferentially in human 
DRG neurons in comparison with rodent species48. Nav1.6 and Nav1.3 channels can also produce a response to 
slow ramplike stimuli49–51. However, Nav1.3 channels present a slow inward current separated by two peaks. The 
first one corresponds to the window current predicted by the overlap of the voltage-dependent activation with the 
fast inactivation and thus it occurs around −40 mV. The second peak occurs at more depolarized potentials (−20 
mV) and it appears to be relatively insensitive to closed-state inactivation52. In our present study, only one peak 
of the ramp current is observed and occurs at −30 mV, ruling out a role for Nav1.3. In addition, Nav1.3 channels 
are expressed only in DRG neurons after nerve injury47. Nav1.6 is highly expressed in large DRG neurons while 
small DRG neurons express low mRNA levels of this sodium channel53. Moreover, the ramp currents generated 
by Nav1.6 channels are smaller than Nav1.7 ramp currents51. For these reasons, we believe that the effect of BPA 
on ramp currents of mice DRG small neurons in our study occurs mainly through Nav1.7 channels, although we 
cannot rule out a small contribution of other sodium channels to ramp currents.
Several reports have shown that estradiol upregulates Nav1.7 and other voltage-gated sodium channels in 
sensory neurons of DRG54, human embryonic stem cell–derived sensory neurons55 and trigeminal ganglia12. 
This implies a contribution of estradiol to hyperalgesia through a genomic action. In contrast, environmentally 
relevant doses of BPA did not alter the expression of voltage-gated Nav1.7, Nav1.8 or Nav1.9 sodium channels 
in the present study. Instead, BPA alters the ramp currents of Nav, most likely acting outside of the cell nucleus 
through activation of PI3K. Several kinases have been reported to be implicated in the regulation of the biophysi-
cal properties of Nav1.7, as PKA and PKC56, ERK1/2 MAP kinase40 and tyrosine kinase57. Hence, it is tempting to 
speculate that PI3K may phosphorylate Nav channels altering their gating properties. When BPA acts in its clas-
sical manner, that is as a transcription factor via estrogen response elements, it behaves as a weak estrogen, since 
its binding activity to ERα and to ERβ is over 1000–10,000-fold lower than that of estradiol58–60. Indeed, BPA has 
less efficiency in the activation of ER and recruits lower amounts of transcriptional coregulators in comparison 
to estradiol, probably due to weaker binding interactions of BPA with ERα61. However, an increasing number 
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of studies during the last twenty years have demonstrated that BPA can elicit cellular and physiological effects 
with the same potency as estradiol, within the nanomolar range to which humans are exposed44,45,62,63. These 
low-dose effects can be explained by the fact that BPA elicits rapid responses via nonclassical estrogen-triggered 
pathways45,64–68. Relevant to our findings, stimulation with estrogens increases ERα-mediated PI3K activity inde-
pendently of gene transcription36 and estradiol can regulate the epithelial sodium channel via a rapid nongenomic 
mechanism involving the activation of the PI3K signaling pathway69. Although it has been reported that E2 can 
also modulate the activity of several ion channels through signaling pathways involving ERK1/29,10, our results 
with the specific blocker of ERK1/2 (PD98059) indicate that this enzyme is not involved in the action of BPA on 
Nav ramp currents in DRG neurons. The acute application of 1 nM BPA (7.7 ± 0.8 min) to eight DRG neurons, had 
no effect on sodium channel ramp currents, indicating that BPA was not exerting a rapid action on sodium chan-
nel ramp currents (results not shown). It is possible that BPA is altering the expression of genes other than sodium 
channels, for example the PI3K gene, through nonclassical estrogen-triggered pathways, and further experiments 
are required to address this hypothesis. In summary, therefore, the effect of BPA on Nav ramp currents in DRG 
neurons must be mediated by nonclassical activation of ERα and subsequent activation of PI3K, similar to some 
of the reported effects of estradiol (Fig. 6).
The fact that our results with BPA are reproduced with 17β-estradiol at the same dose, 1 nM, indicates, a nonclassical 
action in the enhancement of Nav ramp currents. This estrogenic action may contribute to a greater prevalence in women 
of a number of pain conditions, including temporomandibular disorder, irritable bowel syndrome, fibromyalgia, 
and migraine70,71, and also help explain why women exhibit also lower pain thresholds72.
The voltage-gated sodium channel Nav1.7 is expressed in the peripheral nervous system and has a principal 
role in the pathophysiology of pain26,73. Nav1.7 is present not only in nociceptors within the dorsal root ganglia 
but also in sympathetic ganglion neurons25, myenteric neurons74, olfactory neurons75 and pancreatic endocrine 
cells76,77. Hence, a gain of function of this channel induced by BPA could affect not only pain signaling but also 
autonomous sympathetic functions, such as the control of blood vessel caliber and gastrointestinal function. 
Indeed, a case report indicates that occupational exposure to BPA as a consequence of facsimile paper production 
was responsible for inducing the condition of erythema, due to dilated blood vessels and dermatitis78. BPA at 
a no-observed-adverse-effect level (NOAEL: 5 mg/kg/d), has also been reported to influence intestinal barrier 
function and gut nociception41. Furthermore, it has been proposed that mutations of Nav1.7 in human pancreatic 
β-cells may increase susceptibility to development of diabetes via β-cell injury79.
Gain-of-function mutations in SCN9A, which encodes the voltage-gated Nav1.7 channel, produce inherited 
erythromelalgia80 and paroxysmal extreme pain disorder81. Erythromelalgia is characterized by the combina-
tion of recurrent burning pain, warmth and redness of the extremities, and the mutations in SCN9A shift the 
voltage-dependence of Nav1.7 activation in a hyperpolarized direction, increase ramp currents and slow deacti-
vation. Interestingly, these alterations in the biophysical properties of NaV1.7 produce hyperexcitability of DRG 
neurons and hypoexcitability of sympathetic neurons82. It is tempting to speculate that the effects of BPA on pain 
shown in our present results and on erythema78 could be induced by a BPA action on Nav1.7 ramp currents in 
both neuronal types. As a result of the biophysical characteristics of Nav1.7 channels, some of the gain-of-function 
mutations of this channel depolarize the resting potential by ~5 mV without a concomitant effect on the input 
resistance of the neuron83. Our results with BPA on DRG neurons produced the same result, suggesting again that 
the effects of BPA can be explained by a gain of function on Nav1.7 ramp currents.
Figure 6. Cellular model of the potentiation of Nav1.7 ramp currents in DRG neurons by 1 nM BPA. Binding 
of BPA to ERα activates PI3K, which in turn modulates Nav1.7 channels to increase ramp currents. Inhibition 
of ERα by MPP or PI3K by wortmannin abolished the effect of BPA. However, ERβ is not implicated in 
potentiation of Nav1.7 ramp current by BPA in DRG neurons, as DPN had no effect and BPA in the presence of 
PHTPP had effect.
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The main mode of action of BPA is as an agonist of estrogen receptors, although antiandrogenic actions and 
antagonism of thyroid hormone receptors have been reported84,85. In our present work, the action of BPA was 
mediated through activation of ERα, as it was mimicked by the specific agonist of ERα PPT. BPA in the presence 
of the specific antagonist of ERα MPP had no effect, and the action of BPA was present in DRG neurons from 
ERβ−/− male mice. These results indicate that the effect of BPA on Nav ramp currents was mediated by ERα with 
no contribution of ERβ and suggest that the effect of the high concentration of PHTPP, a specific antagonist of 
ERβ, used in the experiment shown in Fig. 5D probably had some unspecific effect. Although the estrogen recep-
tor GPR30 is also expressed in DRG neurons86, the effect of 17β-estradiol through GPR30 is known to inhibit 
pain9. Thus, if BPA is able to activate GPR30 this may limit the extent of the observed increase in nociception and 
merits future work.
In the present study, we have investigated the action of BPA in biological events at molecular and cellular sign-
aling levels, leading to the adverse outcome of altered pain response in the whole animal. According to our results, 
an increase in Nav ramp currents induced by 1 nM BPA through ERα-PI3K activation leads to a higher spike 
firing and then to an increased pain sensitivity. Our results in this particular work followed an Adverse Outcome 
Pathway (AOP) conceptual framework87. We have investigated the action of BPA in biological events at molecular 
and cellular signaling levels, leading to the adverse outcome of altered pain response in the whole animal.
In summary, the present study extends our knowledge on the effects of BPA on adult neurons. We demonstrate 
that BPA at environmentally relevant doses affects the ability to detect noxious stimuli, which is essential for the 
survival of organisms. The nociceptive response to a thermal stimulus is increased in mice treated with BPA at 
the current safety level set by the US Environmental Protection Agency (50 µg/kg/day). Furthermore, incubation 
of dorsal root ganglia sensory neurons with 1 nM BPA for 24–48 h alters voltage-gated Nav ramp currents and 
increases excitability in mouse DRG neurons through the ERα-PI3K pathway. These results should be considered 
when studying the etiology of pain conditions.
Methods
Animals and treatment. Adult male C57BL6 mice aged 3–4 months were used. In order to avoid hor-
monal fluctuation of estrus cycle we decided to use male mice in this study. This allowed us to prevent possible 
interactions with BPA because of higher estradiol levels in females and to reduce variability. Animals were pur-
chased from Servicio de Experimentación Animal (SEA), Universidad Miguel Hernandez de Elche (Elche, Spain). 
Animals were housed (5 mice/cage) in type III cage of polycarbonate plastic (Tecniplast), 530 cm2. We used new 
cages to avoid BPA release as much as posible on heat-treated hardwood bedding, under environmental condi-
tions of 22 °C, and a light cycle of 12 h (8:00 am to 8:00 pm). Mice were maintained on 2014 Teklad Global 14% 
Protein Rodent Maintenance Diet (Harlan Laboratories, Barcelona, Spain), which was free of alfalfa and soybean 
meal, with ad libitum access to food and tap water. The composition of the diet is as follows: crude protein, 14.3%; 
fat, 4%; carbohydrate, 48%; crude fiber, 4.1%; neutral detergent fiber, 18%; ash, 4.7%; energy density, 2.9 kcal/g 
(12.1 kJ/g); calories from protein, 20%; calories from fat, 13%; and calories from carbohydrate, 67%. ERβ−/− mice 
were generated as described elsewhere88 and were supplied originally by the laboratory of Jan-Ake Gustafsson. All 
genetically modified animals and wild types were from the same supplier and the same colony (C57BL6), which 
is grown in Servicio de Experimentación Animal (SEA), Universidad Miguel Hernandez de Elche. Experimental 
procedures were reviewed and approved by the institutional committee for animal care and use of the Universidad 
de Alicante (UA-2017-06-29) and all methods were performed in accordance with the relevant guidelines and 
regulations. Animals were treated humanely and with regard for alleviation of suffering. For behavioral testing (see 
below) BPA was dissolved in tocopherol-stripped corn oil and administered subcutaneously for 8 days in a volume 
of 100 µL. The daily dose used was 50 µg/kg/day. Control animals received a daily dose of vehicle. For patch clamp 
experiments, dorsal root ganglia (DRG) were extracted from untreated mice. In these experiments, BPA or vehicle 
(DMSO 0.000004% v/v) were applied only in vitro after DRG extraction, during DRG neurons culture (see below).
Behavioral testing. We used constant-temperature hot-plate measurements (World Precision Instruments, 
FL). This equipment consisted of a metal plate heated to a preset temperature and a Plexiglass observation cham-
ber. The applied temperature was 50 °C, well above the noxious heat threshold. The holding accuracy of the appa-
ratus is ±0.1 °C as indicated by the manufacturer. We measured the reflex latency of the withdrawal reaction, 
consisting in paw shaking, licking or escape behavior, such as a jump (whichever came first). Mice were habit-
uated to the test apparatus for at least 30 min before testing on each test day and three repeated tests were per-
formed in this period. 20 mice were used for this test, 10 mice treated with BPA and 10 mice treated with vehicle. 
A cut-off for maximal exposure to the hot plate was set at 45 s89. The reflex latency values were in the range of 
observed elsewhere89,90 ≈20 s. An increase in latency was considered analgesia, while a decrease in latency was 
regarded as hyperalgesia.
Primary DRG culture. Previously described culture methods for DRG neurons in adult male mice were 
used91,92. Briefly, 36 male C57BL6 mice were sacrificed using carbon dioxide before confirmation of death, rather 
than cervical dislocation, as the latter may damage cervical DRG. One culture was generated per mouse. Usually, 
6–9 wells were obtained from each culture and a maximum of 3 neuronal recordings were obtained from each 
well. For the experiments with ERβ−/− 3 mice were used. The vertebral column was quickly removed and dis-
sected in ice-cold Hanks’s balanced sodium salt (Sigma Aldrich, Spain). All DRGs from cervical to sacral seg-
ments in both sides of the spinal cord were rapidly removed and enzymatically digested at 37 °C for 15–16 min 
in INCmix solution containing 900 UI/ml collagenase type XI and 3 mg/ml dispase (Gibco, Thermo Fisher 
Scientific). After washing with fresh, enzyme-free DRG medium, single neurons were obtained by gentle agitation 
through a Pasteur pipette. The dissociated DRG neurons were plated into 3.5-cm culture dishes and incubated at 
1 1Scientific RepoRts |         (2019) 9:10306  | https://doi.org/10.1038/s41598-019-46769-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
37 °C and 5% CO2 in the presence of 1 nM BPA or vehicle (control) for 24–48 h. For the experiments with 1 nM 
17-β estradiol (E2), the same protocol was employed.
Patch-clamp recordings. A total of 226 small-diameter (<30 μm) DRG neurons were used for voltage and 
current-clamp recordings within 24–48 h in culture with 1 nM BPA. This includes 18 neurons from ERβ−/− mice 
and 10 neurons for experiments with 1 nM E2. Cells devoid of processes were selected to avoid space-clamp prob-
lems. Patch pipettes were pulled from borosilicate capillaries (World Precision Instruments, FL) using a Flaming/
Brown micropipette puller P-97 (Molecular Devices, CA) and heat-polished at the tip using an MF-830 microforge 
(Narishige, Japan). Electrodes had a resistance of 1–3 MΩ when filled with the pipette solution. For voltage-clamp 
recording, pipette solutions contained (in mM): 140 CsF, 10 NaCl, 4 Mg-ATP, 0,4 Na-GTP, 1 EGTA, 10 HEPES, 
5 Glucose, pH 7.30 (adjusted with CsOH). For current-clamp experiments, pipette solutions contained (in mM): 
140 KCl, 10 NaCl, 4 Mg-ATP, 0,4 Na-GTP, 10 HEPES, 5 Glucose, pH 7.30 (adjusted with KOH). For voltage-clamp 
recordings, the extracellular solution contained the following (in mM): 70 NaCl, 70 Choline Chloride, 3 KCl, 1 
MgCl2 * 6H2O, 1 CaCl2, 20 TEA-Cl, 5 CsCl2, 0.1 CdCl2, 10 HEPES, 10 Glucose, pH 7.4 (adjusted with NaOH). For 
current-clamp experiments, the extracellular solution contained (in mM): 140 NaCl, 3 KCl, 2.4 CaCl2, 10 HEPES, 
10 Glucose, pH 7.4 (adjusted with NaOH). Propyl pyrazole triol (PPT, 1 nM) was used as a specific agonist of 
ERα and methyl-piperidino-pyrazole (MPP, 100 nM) as a specific antagonist of ERα. Diarylpropionitrile (DPN, 
1 nM) was used as a specific agonist of ERβ and phenyltrifluoromethyl pyrazolopyrimidine (PHTPP, 10 μM) as 
a specific antagonist of ERβ. Wortmannin (100 nM) was used as a broad-spectrum PI3K inhibitor. 2-(2-Amino-
3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059, 10 μM) was used as a specific ERK1/2 inhibitor. PPT, 
MPP, PHTPP, Wortmannin, PD98059 and DPN were obtained from Tocris Cookson Ltd (Avonmouth, United 
Kingdom). 17-β estradiol used in Fig. 4 was purchased from Sigma-Aldrich (Madrid, Spain).
Whole-cell recordings in voltage-clamp mode were performed with an Axopatch 200B amplifier (Molecular 
Devices, CA). Data were collected via Digidata 1320 A/D converter (Molecular Devices, CA) at 50 kHz and fil-
tered at 5 kHz. Voltage and current errors were minimized with 80–90% series resistance compensation and linear 
leak currents, and capacitance artifacts were subtracted out using the P/6 method. The amplitude of TTX-sensitive 
sodium channels was estimated via two activation protocols. An I–V curve family of TTX-sensitive plus Nav1.8 
currents were evoked by a series of depolarizing steps from −80 to +50 mV (in increments of 5 mV) at a holding 
potential of −80 mV, which inactivates Nav1.9 channel activity. Because some of the TTX-sensitive current is 
also inactivated at this voltage, a prepulse of 500 ms to −120 mV was applied to remove the fast inactivation of 
these currents, although the inactivation of Nav1.9 persists over this time. This produced an estimation of the 
total sodium current in the neuron minus the Nav1.9 current. To reveal the TTX-sensitive current in isolation, 
a family of currents was recorded using a prepulse of 500 ms to −50 mV before the activating pulse in order to 
inactivate the TTX-sensitive current while leaving the Nav1.8 current intact. This family of currents could then 
be subtracted from the total current in the neuron to view only the TTX-sensitive currents32. Ramp currents are 
expressed as a percentage of the ramp current amplitude in relation to the Nav maximum transient peak current 
evoked with the protocol explained above for each neuron.
Real-time PCR. Three different preparations of dissociated DRG neurons from 6 male mice were treated with 
BPA (1 nM) or vehicle for 24–48 h (measurements performed in duplicate). RNA was extracted using a commer-
cial kit (RNeasy Micro kit, Qiagen, Valencia, CA) according to the manufacturer’s instructions. RNA (0.5 μg) was 
reverse-transcribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, 
CA). Quantitative PCR (RT-PCR) assays were performed using a CFX96 Real Time System (Bio-Rad, Hercules, 
CA). Amplification reactions were carried out in medium containing 200 nM of each primer, 1 μl cDNA, and 1x 
IQTM SYBR® Green Supermix (Bio-Rad). Hypoxanthine guanine phosphoribosyltransferase (Hprt) was used as 
the normalization gene. (RT-PCR primers, see Supplementary Fig. 3).
Samples were subjected to the following conditions: 3 min at 95 °C, 40 cycles (5 s at 95 °C, 5 s at 60 °C, and 10 s 
at 72 °C), and a melting curve of 65–95 °C. Genes were considered as positively amplified when the Ct values were 
lower than 35 (Ct cut-off value = 35 cycles). The resulting values were analyzed with CFX Manager Version 1.6 
(Bio-Rad) and are expressed as the relative expression with respect to control values (2−ΔΔCT)93.
Statistical analysis. For statistical analysis, GraphPad Prism (GraphPad software, Inc., CA), Sigmaplot 12.0 
(Systat Software, Inc.) or SPSS 22.0 software (Statistical Package for Social Sciences, Chicago, IL, USA) were 
used. Data are expressed as the mean ± SEM. To assess differences between exposure groups, we used unpaired 
Student’s test. When data did not pass the parametric test, the Mann-Whitney or Kruskal-Wallis test was used. 
In Fig. 1 a one-way ANOVA for repeated measures was applied to assess the differences between treatments 
(vehicle and BPA), as well as any interactions between data of one treatment. Post-hoc pairwise comparisons 
using Bonferroni’s test were carried out when a 0.05 level of significance was obtained. Values of P < 0.05 were 
considered to be statistically significant. In Fig. 5F, we used one-way ANOVA followed by the Holm-Sidak test to 
compare control group vs the rest of experimental groups.
References
 1. Wetherill, Y. B. et al. In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol 24, 178–198 (2007).
 2. Calafat, A. M., Ye, X., Wong, L. Y., Reidy, J. A. & Needham, L. L. Exposure of the U.S. population to bisphenol A and 4-tertiary-
octylphenol: 2003-2004. Environ Health Perspect 116, 39–44 (2008).
 3. Gore, A. C. et al. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev 36, 
E1–E150 (2015).
 4. Aloisi, A. M. et al. Exposure to the estrogenic pollutant bisphenol A affects pain behavior induced by subcutaneous formalin 
injection in male and female rats. Brain Res 937, 1–7 (2002).
1 2Scientific RepoRts |         (2019) 9:10306  | https://doi.org/10.1038/s41598-019-46769-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
 5. Vermeer, L. M., Gregory, E., Winter, M. K., McCarson, K. E. & Berman, N. E. Exposure to bisphenol A exacerbates migraine-like 
behaviors in a multibehavior model of rat migraine. Toxicol Sci 137, 416–427 (2014).
 6. Vom Saal, F. S. et al. Bisphenol A (BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in 
pregnant rhesus monkeys: Relevance for human exposures. Reprod Toxicol 45, 105–116, https://doi.org/10.1016/j.
reprotox.2014.01.007 (2014).
 7. Amandusson, A. & Blomqvist, A. Estrogenic influences in pain processing. Front Neuroendocrinol 34, 329–349 (2013).
 8. Tang, B., Ji, Y. & Traub, R. J. Estrogen alters spinal NMDA receptor activity via a PKA signaling pathway in a visceral pain model in 
the rat. Pain 137, 540–549 (2008).
 9. Lu, Y. et al. 17beta-estradiol rapidly attenuates P2X3 receptor-mediated peripheral pain signal transduction via ERalpha and GPR30. 
Endocrinology 154, 2421–2433 (2013).
 10. Qu, Z. W. et al. 17beta-Estradiol Enhances ASIC Activity in Primary Sensory Neurons to Produce Sex Difference in Acidosis-
Induced Nociception. Endocrinology 156, 4660–4671 (2015).
 11. Payrits, M. et al. Estradiol Sensitizes the Transient Receptor Potential Vanilloid 1 Receptor in Pain Responses. Endocrinology 158, 
3249–3258 (2017).
 12. Bi, R. Y. et al. Estradiol upregulates voltage-gated sodium channel 1.7 in trigeminal ganglion contributing to hyperalgesia of inflamed 
TMJ. PLoS One 12, e0178589 (2017).
 13. Alonso-Magdalena, P. et al. Bisphenol-A acts as a potent estrogen via non-classical estrogen triggered pathways. Molecular and 
cellular endocrinology 355, 201–207, https://doi.org/10.1016/j.mce.2011.12.012 (2012).
 14. Soriano, S. et al. Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen 
receptor beta. PLoS One 7, e31109, https://doi.org/10.1371/journal.pone.0031109 (2012).
 15. Villar-Pazos, S. et al. Molecular mechanisms involved in the non-monotonic effect of bisphenol-a on ca2+ entry in mouse pancreatic 
beta-cells. Sci Rep 7, 11770 (2017).
 16. Soriano, S. et al. Effects of Bisphenol A on ion channels: Experimental evidence and molecular mechanisms. Steroids 111, 12–20 
(2016).
 17. Asano, S., Tune, J. D. & Dick, G. M. Bisphenol A activates Maxi-K (K(Ca)1.1) channels in coronary smooth muscle. British journal 
of pharmacology 160, 160–170, https://doi.org/10.1111/j.1476-5381.2010.00687.x (2010).
 18. Deutschmann, A., Hans, M., Meyer, R., Haberlein, H. & Swandulla, D. Bisphenol A inhibits voltage-activated Ca(2+) channels in 
vitro: mechanisms and structural requirements. Molecular pharmacology 83, 501–511, https://doi.org/10.1124/mol.112.081372 (2013).
 19. Wang, Q. et al. Inhibition of voltage-gated sodium channels by bisphenol A in mouse dorsal root ganglion neurons. Brain Res 1378, 
1–8, https://doi.org/10.1016/j.brainres.2011.01.022 (2011).
 20. Dib-Hajj, S. D., Cummins, T. R., Black, J. A. & Waxman, S. G. Sodium channels in normal and pathological pain. Annu Rev Neurosci 
33, 325–347 (2010).
 21. Cox, J. J. et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894–898, https://doi.
org/10.1038/nature05413 (2006).
 22. Drenth, J. P. & Waxman, S. G. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. The 
Journal of clinical investigation 117, 3603–3609, https://doi.org/10.1172/JCI33297 (2007).
 23. Gamble, G. D. & Milne, R. J. Repeated exposure to sham testing procedures reduces reflex withdrawal and hot-plate latencies: 
attenuation of tonic descending inhibition? Neuroscience letters 96, 312–317 (1989).
 24. Sangameswaran, L. et al. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root 
ganglia. J Biol Chem 272, 14805–14809 (1997).
 25. Toledo-Aral, J. J. et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral 
neurons. Proc Natl Acad Sci USA 94, 1527–1532 (1997).
 26. Dib-Hajj, S. D., Yang, Y., Black, J. A. & Waxman, S. G. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci 14, 
49–62 (2013).
 27. Momin, A. & Wood, J. N. Sensory neuron voltage-gated sodium channels as analgesic drug targets. Current opinion in neurobiology 
18, 383–388, https://doi.org/10.1016/j.conb.2008.08.017 (2008).
 28. Jardin, I. et al. TRPs in Pain Sensation. Front Physiol 8, 392 (2017).
 29. Golowasch, J. et al. Membrane capacitance measurements revisited: dependence of capacitance value on measurement method in 
nonisopotential neurons. Journal of neurophysiology 102, 2161–2175, https://doi.org/10.1152/jn.00160.2009 (2009).
 30. Harper, A. A. & Lawson, S. N. Conduction velocity is related to morphological cell type in rat dorsal root ganglion neurones. J 
Physiol 359, 31–46 (1985).
 31. Harper, A. A. & Lawson, S. N. Electrical properties of rat dorsal root ganglion neurones with different peripheral nerve conduction 
velocities. J Physiol 359, 47–63 (1985).
 32. Rush, A. M. et al. Contactin regulates the current density and axonal expression of tetrodotoxin-resistant but not tetrodotoxin-
sensitive sodium channels in DRG neurons. Eur J Neurosci 22, 39–49 (2005).
 33. Cummins, T. R. et al. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory 
neurons. J Neurosci 19, RC43 (1999).
 34. Cummins, T. R., Howe, J. R. & Waxman, S. G. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells 
expressing the hNE/PN1 sodium channel. J Neurosci 18, 9607–9619 (1998).
 35. Bennett, H. L., Gustafsson, J. A. & Keast, J. R. Estrogen receptor expression in lumbosacral dorsal root ganglion cells innervating the 
female rat urinary bladder. Auton Neurosci 105, 90–100 (2003).
 36. Simoncini, T. et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 
538–541 (2000).
 37. Migliaccio, A., Castoria, G. & Auricchio, F. Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic 
implications. The international journal of biochemistry & cell biology 39, 1343–1348, https://doi.org/10.1016/j.biocel.2006.12.009 
(2007).
 38. Levin, E. R. & Hammes, S. R. Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. Nature reviews. 
Molecular cell biology 17, 783–797, https://doi.org/10.1038/nrm.2016.122 (2016).
 39. Alonso-Magdalena, P. et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS One 3, e2069, https://doi.
org/10.1371/journal.pone.0002069 (2008).
 40. Stamboulian, S. et al. ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating 
properties. J Neurosci 30, 1637–1647 (2010).
 41. Braniste, V. et al. Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal 
exposure in rats. Proc Natl Acad Sci USA 107, 448–453 (2010).
 42. Vandenberg, L. N. et al. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ 
Health Perspect 118, 1055–1070, https://doi.org/10.1289/ehp.0901716 (2010).
 43. Vandenberg, L. N., Chahoud, I., Padmanabhan, V., Paumgartten, F. J. & Schoenfelder, G. Biomonitoring studies should be used by 
regulatory agencies to assess human exposure levels and safety of bisphenol A. Environ Health Perspect 118, 1051–1054, https://doi.
org/10.1289/ehp.0901717 (2010).
 44. Nagel, S. C. et al. Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the 
xenoestrogens bisphenol A and octylphenol. Environ Health Perspect 105, 70–76 (1997).
13Scientific RepoRts |         (2019) 9:10306  | https://doi.org/10.1038/s41598-019-46769-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
 45. Nadal, A. et al. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to 
estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci USA 97, 11603–11608 (2000).
 46. Taylor, J. A. et al. Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure. Environ 
Health Perspect 119, 422–430, https://doi.org/10.1289/ehp.1002514 (2011).
 47. Dib-Hajj, S. D. & Waxman, S. G. Diversity of composition and function of sodium channels in peripheral sensory neurons. Pain 156, 
2406–2407, https://doi.org/10.1097/j.pain.0000000000000353 (2015).
 48. Han, C. et al. Human Na(v)1.8: enhanced persistent and ramp currents contribute to distinct firing properties of human DRG 
neurons. Journal of neurophysiology 113, 3172–3185, https://doi.org/10.1152/jn.00113.2015 (2015).
 49. Cummins, T. R. & Waxman, S. G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly 
repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J Neurosci 17, 3503–3514 
(1997).
 50. Cummins, T. R. et al. Nav1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences 
after expression in a mammalian cell line and in spinal sensory neurons. J Neurosci 21, 5952–5961 (2001).
 51. Herzog, R. I., Cummins, T. R., Ghassemi, F., Dib-Hajj, S. D. & Waxman, S. G. Distinct repriming and closed-state inactivation 
kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol 551, 741–750, https://doi.org/10.1113/
jphysiol.2003.047357 (2003).
 52. Estacion, M. & Waxman, S. G. The response of Na(V)1.3 sodium channels to ramp stimuli: multiple components and mechanisms. 
Journal of neurophysiology 109, 306–314, https://doi.org/10.1152/jn.00438.2012 (2013).
 53. Black, J. A. et al. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. Brain Res Mol Brain Res 43, 
117–131 (1996).
 54. Hu, F. et al. 17beta-Estradiol regulates the gene expression of voltage-gated sodium channels: role of estrogen receptor alpha and 
estrogen receptor beta. Endocrine 41, 274–280 (2012).
 55. Greaves, E., Grieve, K., Horne, A. W. & Saunders, P. T. Elevated peritoneal expression and estrogen regulation of nociceptive ion 
channels in endometriosis. J Clin Endocrinol Metab 99, E1738–1743 (2014).
 56. Cantrell, A. R. & Catterall, W. A. Neuromodulation of Na+ channels: an unexpected form of cellular plasticity. Nat Rev Neurosci 2, 
397–407, https://doi.org/10.1038/35077553 (2001).
 57. Li, Y. et al. Nav1.7 is phosphorylated by Fyn tyrosine kinase which modulates channel expression and gating in a cell type-dependent 
manner. Mol Pain 14, 1744806918782229, https://doi.org/10.1177/1744806918782229 (2018).
 58. Kuiper, G. G. et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139, 
4252–4263 (1998).
 59. Andersen, H. R. et al. Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environ 
Health Perspect 107(Suppl 1), 89–108 (1999).
 60. Fang, H. et al. Quantitative comparisons of in vitro assays for estrogenic activities. Environ Health Perspect 108, 723–729 (2000).
 61. Li, Y. et al. Differential in Vitro Biological Action, Coregulator Interactions, and Molecular Dynamic Analysis of Bisphenol A (BPA), 
BPAF, and BPS Ligand-ERalpha Complexes. Environ Health Perspect 126, 017012 (2018).
 62. Steinmetz, R., Brown, N. G., Allen, D. L., Bigsby, R. M. & Ben-Jonathan, N. The environmental estrogen bisphenol A stimulates 
prolactin release in vitro and in vivo. Endocrinology 138, 1780–1786, https://doi.org/10.1210/endo.138.5.5132 (1997).
 63. Nadal, A. et al. Extranuclear-initiated estrogenic actions of endocrine disrupting chemicals: Is there toxicology beyond paracelsus? 
The Journal of steroid biochemistry and molecular biology 176, 16–22, https://doi.org/10.1016/j.jsbmb.2017.01.014 (2018).
 64. Quesada, I. et al. Low doses of the endocrine disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate 
transcription factor CREB. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16, 
1671–1673, https://doi.org/10.1096/fj.02-0313fje (2002).
 65. Alonso-Magdalena, P. et al. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a 
nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect 113, 969–977 (2005).
 66. Vinas, R. & Watson, C. S. Bisphenol S disrupts estradiol-induced nongenomic signaling in a rat pituitary cell line: effects on cell 
functions. Environ Health Perspect 121, 352–358, https://doi.org/10.1289/ehp.1205826 (2013).
 67. Alyea, R. A. & Watson, C. S. Differential regulation of dopamine transporter function and location by low concentrations of 
environmental estrogens and 17beta-estradiol. Environ Health Perspect 117, 778–783, https://doi.org/10.1289/ehp.0800026 (2009).
 68. Jeng, Y. J. & Watson, C. S. Combinations of physiologic estrogens with xenoestrogens alter ERK phosphorylation profiles in rat 
pituitary cells. Environ Health Perspect 119, 104–112, https://doi.org/10.1289/ehp.1002512 (2011).
 69. Qi, D. et al. 17beta-estradiol suppresses lipopolysaccharide-induced acute lung injury through PI3K/Akt/SGK1 mediated up-
regulation of epithelial sodium channel (ENaC) in vivo and in vitro. Respir Res 15, 159 (2014).
 70. Gupta, S., McCarson, K. E., Welch, K. M. & Berman, N. E. Mechanisms of pain modulation by sex hormones in migraine. Headache 
51, 905–922, https://doi.org/10.1111/j.1526-4610.2011.01908.x (2011).
 71. Artero-Morales, M., Gonzalez-Rodriguez, S. & Ferrer-Montiel, A. TRP Channels as Potential Targets for Sex-Related Differences in 
Migraine Pain. Frontiers in molecular biosciences 5, 73, https://doi.org/10.3389/fmolb.2018.00073 (2018).
 72. Riley, J. L. 3rd, Robinson, M. E., Wise, E. A., Myers, C. D. & Fillingim, R. B. Sex differences in the perception of noxious experimental 
stimuli: a meta-analysis. Pain 74, 181–187 (1998).
 73. Yang, Y., Mis, M. A., Estacion, M., Dib-Hajj, S. D. & Waxman, S. G. NaV1.7 as a Pharmacogenomic Target for Pain: Moving Toward 
Precision Medicine. Trends Pharmacol Sci 39, 258–275 (2018).
 74. Muroi, Y. et al. Selective silencing of Na(V)1.7 decreases excitability and conduction in vagal sensory neurons. J Physiol 589, 
5663–5676 (2011).
 75. Weiss, J. et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature 472, 186–190 (2011).
 76. Gopel, S., Kanno, T., Barg, S., Galvanovskis, J. & Rorsman, P. Voltage-gated and resting membrane currents recorded from B-cells in 
intact mouse pancreatic islets. J Physiol 521(Pt 3), 717–728 (1999).
 77. Braun, M. et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin 
secretion. Diabetes 57, 1618–1628 (2008).
 78. Akita, H., Washimi, Y., Akamatsu, H., Fukui, Y. & Matsunaga, K. Erythema-multiforme-like occupational contact dermatitis due to 
bisphenol A. Contact Dermatitis 45, 305 (2001).
 79. Hoeijmakers, J. G., Faber, C. G., Merkies, I. S. & Waxman, S. G. Channelopathies, painful neuropathy, and diabetes: which way does 
the causal arrow point? Trends Mol Med 20, 544–550 (2014).
 80. Yang, Y. et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. Journal of 
medical genetics 41, 171–174 (2004).
 81. Dib-Hajj, S. D. et al. Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. 
Mol Pain 4, 37 (2008).
 82. Rush, A. M. et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl 
Acad Sci USA 103, 8245–8250, https://doi.org/10.1073/pnas.0602813103 (2006).
 83. Han, C. et al. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons 
correlate with autonomic symptoms in small fibre neuropathy. Brain 135, 2613–2628 (2012).
 84. Moriyama, K. et al. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab 87, 5185–5190 
(2002).
1 4Scientific RepoRts |         (2019) 9:10306  | https://doi.org/10.1038/s41598-019-46769-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
 85. Lee, H. J., Chattopadhyay, S., Gong, E. Y., Ahn, R. S. & Lee, K. Antiandrogenic effects of bisphenol A and nonylphenol on the 
function of androgen receptor. Toxicol Sci 75, 40–46 (2003).
 86. Lu, C. L. et al. Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology 
137, 1040–1050, https://doi.org/10.1053/j.gastro.2009.03.047 (2009).
 87. Ankley, G. T. et al. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. 
Environmental toxicology and chemistry 29, 730–741, https://doi.org/10.1002/etc.34 (2010).
 88. Krege, J. H. et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95, 
15677–15682 (1998).
 89. Bajic, D. et al. Cannabinoid Receptor Type 1 in the Brain Regulates the Affective Component of Visceral Pain in Mice. Neuroscience 
384, 397–405, https://doi.org/10.1016/j.neuroscience.2018.05.041 (2018).
 90. Nissen, N. I. et al. Augmenting the antinociceptive effects of nicotinic acetylcholine receptor activity through lynx1 modulation. 
PLoS One 13, e0199643. https://doi.org/10.1371/journal.pone.0199643 (2018).
 91. Shields, S. D. et al. Sodium channel Na(v)1.7 is essential for lowering heat pain threshold after burn injury. J Neurosci 32, 
10819–10832 (2012).
 92. Sleigh, J. N., Weir, G. A. & Schiavo, G. A simple, step-by-step dissection protocol for the rapid isolation of mouse dorsal root ganglia. 
BMC Res Notes 9, 82 (2016).
 93. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods 25, 402–408 (2001).
Acknowledgements
The authors thank Maria Luisa Navarro and Salomé Ramon for their excellent technical assistance and Martyn 
Mahaut-Smith for editing the English language. The authors’ laboratories are funded by the Ministerio de 
Economía, Industria y Competitividad, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo 
Regional (FEDER), BFU2017-86579-R (A.N.) and Generalitat Valenciana, PROMETEOII/2015/016 (A.N.). 
CIBERDEM is an initiative of the Instituto de Salud Carlos III. J.-A. G. was supported by a fellowship from the A. 
Welch Foundation (Grant E-0004).
Author Contributions
S.S., M.G.-R., L.M., P.A.-M., J.M.-P. performed, analyzed experiments and prepared Figures 1–6. A.N., J.M.-P. 
and S.S. designed the experiments. All authors contributed to the discussion and reviewed and edited the 
manuscript. A.N., J.M.-P. P.A.-M., E.F. and S.S. wrote the manuscript. A.N. and J.M.-P. supervised the work. A.N. 
is its guarantor.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46769-6.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
